DK0841949T3 - Anvendelse af saccharid-konjugater - Google Patents

Anvendelse af saccharid-konjugater

Info

Publication number
DK0841949T3
DK0841949T3 DK96921895T DK96921895T DK0841949T3 DK 0841949 T3 DK0841949 T3 DK 0841949T3 DK 96921895 T DK96921895 T DK 96921895T DK 96921895 T DK96921895 T DK 96921895T DK 0841949 T3 DK0841949 T3 DK 0841949T3
Authority
DK
Denmark
Prior art keywords
conjugate
saccharide conjugates
present
saccharide
therapeutic
Prior art date
Application number
DK96921895T
Other languages
English (en)
Inventor
Manfred Wiessler
Konrad Beyreuther
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK0841949T3 publication Critical patent/DK0841949T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
DK96921895T 1995-07-05 1996-07-05 Anvendelse af saccharid-konjugater DK0841949T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19524515A DE19524515A1 (de) 1995-07-05 1995-07-05 Saccharid-Konjugate

Publications (1)

Publication Number Publication Date
DK0841949T3 true DK0841949T3 (da) 2006-08-21

Family

ID=7766090

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921895T DK0841949T3 (da) 1995-07-05 1996-07-05 Anvendelse af saccharid-konjugater

Country Status (8)

Country Link
US (1) US6489302B1 (da)
EP (1) EP0841949B1 (da)
JP (1) JPH11508565A (da)
AT (1) ATE324119T1 (da)
DE (2) DE19524515A1 (da)
DK (1) DK0841949T3 (da)
ES (1) ES2264141T3 (da)
WO (1) WO1997002046A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
EP1363673A2 (en) * 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
EP1572067A4 (en) * 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
WO2003059149A2 (en) * 2001-12-21 2003-07-24 Threshold Pharmaceuticals, Inc. Methods for cancer imaging
AU2003225763A1 (en) * 2002-03-11 2003-09-29 Visen Medical, Inc. Optical imaging probes
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
JP2006521562A (ja) * 2003-03-07 2006-09-21 スレショルド ファーマシューティカルズ インコーポレイティッド 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法
US7943586B2 (en) * 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005074996A2 (en) 2004-01-30 2005-08-18 Xenoport, Inc. Lat1 transporter expressed in blood brain barrier cells
WO2005075684A2 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier
WO2005075992A1 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Mct1 transporter expressed in blood brain barrier cells
US20050170391A1 (en) * 2004-01-30 2005-08-04 Xenoport, Inc. TAUT1 transporters expressed in blood brain barrier cells
WO2005077424A2 (en) * 2004-02-05 2005-08-25 David Rubin Conjugate for destroying cancer cells
KR101226631B1 (ko) * 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US20070015771A1 (en) * 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) * 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20060146812A1 (en) * 2004-12-30 2006-07-06 Lexmark International, Inc. Methods and systems for routing data using a destination server
WO2007016160A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Svct2 transporters expressed in blood brain barrier cells
US7670782B2 (en) * 2005-07-29 2010-03-02 Xenoport, Inc. Screening of compounds for CAT1 transporter activity
US7704695B2 (en) * 2005-07-29 2010-04-27 Xenoport, Inc. Screening of compounds for BGT1 transporter activity
US7691584B2 (en) * 2005-07-29 2010-04-06 Xenoport, Inc. Screening of compounds for OCT3 transporter activity
WO2007016144A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Octn2 transporters expressed in blood brain barrier cells
WO2007016159A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Gat2 transporters expressed in blood brain barrier cells
WO2007052308A2 (en) * 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
SE533540C2 (sv) * 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
CN102811746A (zh) * 2010-01-18 2012-12-05 得克萨斯系统大学评议会 用于纳米颗粒介导的癌细胞靶向递送的方法和组合物
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
CN110922437B (zh) * 2018-09-20 2023-11-03 凯惠科技发展(上海)有限公司 一种葡萄糖类化合物、药物组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD122386A1 (da) 1975-06-24 1976-10-05
DD123457A1 (da) * 1975-12-18 1976-12-20
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4457918A (en) * 1982-05-12 1984-07-03 The General Hospital Corporation Glycosides of vitamins A, E and K
FR2551068B1 (fr) * 1983-08-30 1986-03-21 Choay Sa Nouveaux derives de nitrosourees, leurs procedes de preparation et compositions therapeutiques les contenant
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
EP0320942A3 (en) * 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
DE3829899C2 (de) * 1988-09-02 1994-12-15 Reutter Werner Glyceringlycophosphatide und diese enthaltende pharmazeutische Mittel zur Bekämpfung von Hauterkrankungen
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
JPH0363224A (ja) * 1989-08-02 1991-03-19 Kureha Chem Ind Co Ltd プロトカテキュアルデヒド類の糖誘導体
JP3072025B2 (ja) * 1989-11-06 2000-07-31 明治乳業株式会社 抗癌剤
JPH0784481B2 (ja) 1991-02-21 1995-09-13 株式会社デイ・デイ・エス研究所 カルボキシメチルマンノグルカン及びその誘導体
JP3006902B2 (ja) * 1991-03-29 2000-02-07 日本テルペン化学株式会社 モノテルペン配糖体
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
DE4229903A1 (de) * 1992-09-08 1994-03-10 Bayer Ag Neue Acetale von Ketophosphamid und Alkylglycosiden
JP3253366B2 (ja) 1992-09-21 2002-02-04 日本テルペン化学株式会社 血糖上昇抑制剤
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
JPH0748264A (ja) 1993-08-06 1995-02-21 Nippon Terupen Kagaku Kk アルドース還元酵素阻害剤
FR2712888B1 (fr) * 1993-11-23 1996-02-09 Bioeurope Utilisation de alpha-D-alkylglucopyranosides et esters de ceux-ci pour la préparation de prodrogues capables de traverser la barrière hématoencéphalique, prodrogues obtenues et précurseurs de celles-ci.

Also Published As

Publication number Publication date
EP0841949A2 (de) 1998-05-20
ES2264141T3 (es) 2006-12-16
WO1997002046A2 (de) 1997-01-23
DE59611341D1 (de) 2006-06-01
DE19524515A1 (de) 1997-01-09
EP0841949B1 (de) 2006-04-26
US6489302B1 (en) 2002-12-03
JPH11508565A (ja) 1999-07-27
WO1997002046A3 (de) 1997-07-03
ATE324119T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
ATE324119T1 (de) Verwendung von saccharid-konjugaten
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
FR2716363B1 (fr) Instrument de thérapie endoscopique.
PT1333887E (pt) Metodo de tratamento de desordens musculares
ATE232396T1 (de) Oxydiertes thymosin beta 4
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
BR9506820A (pt) Derivados de 4-amino de ácido micofenólico
ATE335515T1 (de) Morpholinobildgebung und therapie
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ATE355288T1 (de) Verbindungen und therapeutische methoden
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
BR0009211A (pt) Derivados de resorcinol
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
MY124071A (en) Treatment of viral disease in swine
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
NO20005548L (no) Mykobakterieinhibitorer
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários